ACELEX capsule 2mg - Tissue Selective COX-2 inhibitor CrystalGenomics Acelex NC Jan2016. Acelex® (polmacoxib) is a non-steroidal anti-inflammatory drug (NSAID), specifically a COX-2 inhibitor, for the treatment of symptoms associated with arthritis. Suffering from joints pain which might have been due to age or other reason. Acelex capsule 2 mg is one of new drug in the market for joints pain relief.

1. January 2016
Overview of
Acelex®
(Polmacoxib),
a Novel NSAID
for Osteoarthritis

2. To become a fully integrated biopharmaceutical company in Korea and expand
internationally through collaborations and partnerships
To become a fully integrated biopharmaceutical company in Korea and expand
internationally through collaborations and partnershipsVisionVision
2000.07 Founded
2003.09 Publication in Nature (article and cover based on platform technology)
2006.01 IPO on KOSDAQ
2006.10 Established US subsidiary, CG Pharmaceuticals, Inc. for clinical development
2012.06 Designated by the Korean government as one of the ‘KIPC’ certified companies
2014.07 Designated by the Korean government as one of the ‘K-BrainPower’ companies
2015.02 Obtained the NDA approval from MFDS for Acelex®
in Korea (osteoarthritis)
2015.09 Launch of Acelex®
in Korea
2000.07 Founded
2003.09 Publication in Nature (article and cover based on platform technology)
2006.01 IPO on KOSDAQ
2006.10 Established US subsidiary, CG Pharmaceuticals, Inc. for clinical development
2012.06 Designated by the Korean government as one of the ‘KIPC’ certified companies
2014.07 Designated by the Korean government as one of the ‘K-BrainPower’ companies
2015.02 Obtained the NDA approval from MFDS for Acelex®
in Korea (osteoarthritis)
2015.09 Launch of Acelex®
in Korea
HistoryHistory
Next generation NSAID, Acelex®
for osteoarthritis (first-in-class)
Novel antibiotic candidate for MRSA infection, CG400549 (first-in-class)
Molecular-targeted cancer therapeutic, CG200745 (best-in-class)
Next generation NSAID, Acelex®
for osteoarthritis (first-in-class)
Novel antibiotic candidate for MRSA infection, CG400549 (first-in-class)
Molecular-targeted cancer therapeutic, CG200745 (best-in-class)
Key ProgramsKey Programs
CrystalGenomics is a commercial stage biopharmaceutical company with
innovative platform technologies dedicated in the discovery and
development of novel pharmaceuticals in unmet medical need areas.
Corporate Overview

3. Platform Technology : Overview
Integration of in vitro experiments and in silico technology enables the company to streamline
the drug discovery process from gene to drug.
Lead Discovery ( SCPTM
)
SCPTM
NMR
Virtual
Screening
In vitro Assay
SCPTM
Library
SCPTM
Screening
Synchrotron, NMR
Structure Determination ( SPSTM
)
AGTC
TCAG
Target
Selection
Lead Optimization and Candidate Selection ( SDFTM
)
In vivo
Evaluation
DMPK
Toxicology
Pharmacology
Biological
Evaluations
Target Assays
Cellular Assays
In vitro DMPK
Drug Design &
MediChem
SDFTM
X-ray
SDFTM
Informatics
Parallel Synthesis
Pre-clinical
Candidate
Lead / Target
Complex
O
R2
R3
O
N
R1
IND-enabling Tox
(CRO in EU,USA)

4. CG Has Global Standard Drug Discovery Capabilities
Viagra®
(sildenafil)
Cialis®
(tadalafil)
Levitra ®
(vardenafil)
CrystalGenomics was the first group to solve the complex crystal structure of PDE5 using
SPS™ technology: Nature 425, 98-102 (2003).

5. •5
•SBI BIOTECH CO., LTD.
Former & Current Alliance Partners

6. R&D Pipeline
Disease Target
Candidat
e
Indication Phase I Ph II Ph III
1
Infectious Disease MRSA
2
Cancer MDS
Area Product Indication Current Status Partners
2
Cancer Pancreatic cancer
1
Cancer AML
1
CNS Alzheimer’s Disease
2
Metabolic Anemia
1. First-in-class , 2. Best-in-class
Novel Therapeutics Pipeline
Inflammation 1
Acelex®
Osteoarthritis
• Approved by the MFDS (Feb. 2015),
• Launched in Korea (Sep. 2015)
• Partnered with TR-Pharm for Turkey & MENA (Jan. 2016)
Area Indication Discovery Preclinical Ph I Ph II Ph III NDA

7. Next Generation NSAID,
Acelex®
(polmacoxib)
(Novel NSAID with Tissue-Selective Activity)

8. Acelex® 2mg Capsule
Novel NSAID for the relief of signs and symptoms of osteoarthritis
▪ Global market for arthritis drugs was USD 50B, of which
$17.5B consisted of COX-2 drugs & NSAIDs but existing
therapies have CV and GI safety issues and there is a great
unmet medical need for a safer drug1
▪ 16,344 deaths and 545,452 hospital admissions from GI
bleeding in 2006 and heavy NSAID usage partially to blame2
▪ Celebrex®
(Pfizer) - 2012 global sales was USD 2.7B and
USD 51M+ sales in Korea with double digit CAGR (2012)
▪ Approved by the MFDS of Korea (Feb. 5, 2015)
▪ Launched in September 2015 (marketed and sold by
Dong-A ST)
▪ Partnered with TR-Pharm for commercialization of
Acelex in Turkey & MENA region, covering 19 countries
(Jan. 2016)
1
IMS Top Line Industry Data (2009)
2
Statistical Brief #65 Healthcare Cost and Utilization Project Jan. 2009 Agency for Healthcare Research & Quality, Rockville, MD
Acelex Target Market
Acelex®
, A Novel NSAID for Osteoarthritis

9. Acelex®
, Tissue Selective NSAID for Osteoarthritis
Category Projected Advantages of Acelex
Efficacy
• ​Quicker onset of relief from the signs and symptoms of OA over celecoxib.
• Achieved superior PGA (Physicians Global Assessment) scores compared to celecoxib.
Dose • Only 2 mg/day dose, the lowest daily dose among all known NSAIDs.
Administration
Frequency
• Convenient once-a-day dosing regimen unlike most other NSAIDs.
Gastrointestinal
Side Effects
• Significantly improved GI safety in comparison with traditional NSAIDs on the market.
Cardiovascular
Side Effects
• Acelex’s tissue-selective-COX2-inhibition mechanism is projected to provide a meaningful
enhancement of cardiovascular safety over currently available NSAIDs.
< Acelex® 2mg Capsule >
Tissue-Selective NSAID for the Relief of Signs Symptoms of Osteoarthritis (OA)
• Approved by the MFDS (Feb. 2015),
• Launched in Korea by Dong-A ST (Sep. 2015)
• Partnered with TR-Pharm for Turkey & MENA (Jan. 2016)

10. 1
OA Market Characteristics
 Osteoarthritis (OA) is characterized by
deterioration of cartilage tissue within joint
and involves entire joint1
• Nearby muscles
• Underlying bone
• Ligaments
• Joint lining (synovium)
• Joint cover (capsule)
 The cause is still not completely known and there is no cure
 Aging of population is driving growth of OA market
• Cartilage degradation is positively correlated with increasing age and is most
common in people over 55 years of age
 Obesity epidemic resulting in more wear and tear on joints is also contributing
to growth of OA market
1
Business Insights © 2009; The Autoimmune Outlook to 2013

11. 1
Positioning of A Novel NSAID, Acelex®
for Osteoarthritis
• Acelexwould be the first, tissue-selective and once-a-day osteoarthritis drug with a novel
mode of action that specifically targets affected joints to relieve pain and restores
mobility
• Acelex 2 mg once-a-day could provide more rapid onset of relief from the signs and
symptoms of osteoarthritis in comparison with Celebrex 200 mg once-a-day without
added safety risk.

12. 1
Product Profiles of Marketed NSAIDs and COX-2 Inhibitors
Classification Drug Products Characteristics GI Risk CV Risk
Traditional
NSAIDs
Traditional NSAIDs:
naproxen,
ibuprofen,
diclofenac
- Low selectivity
- 2–4 times/day (75–2,400 mg/day)
Very high
Moderate or
high
Vimovo (Pozen,
AstraZeneca)
- Naproxen + Esomeprazole
-Twice/day
- FDA warning for long-term use
- Sales volume is small.
Moderate Moderate
COX-2
Inhibitors
Celebrex®
(Celecoxib: Pfizer)
- Sales in 2010 was $2,374M
- Once or twice/day (200–400
mg/day)
Low Moderate
Arcoxia®
(Etoricoxib: Merck)
- Sales in 2010 was $398M in EU
- Not approved in the US
- Once/day (30–120 mg/day)
Low High
Tissue
Selective
COX-2 Inhibitor
Acelex®
(Polmacoxib: CG)
- ‘Tissue selective’ COX-2 inhibitor
- Once/day (2 mg/day)
Low
None
observed
to date

13. 1
Whole Blood, Blood
Vessels, CV Tissues
Inflamed Joints (OA, RA)
Limited side effects Good efficacy
Polmacoxib
COX-2
CA
CA >> COX-2 
Preferred binding to CA
CA << COX-2 
Preferred binding to COX-2
Polmacoxib, a dual inhibitor of COX-2 and human CA (carbonic anhydrase), does
not inhibit COX-2 in CA-rich tissues (e.g. CV system), but it fully inhibits COX-2 in
CA-deficient tissues (inflamed joints).
Mechanism of Polmacoxib

14. 1
Summary of Clinical Studies for Acelex
Phase Type
ClinicalTrials.gov
Identifier
Trial
Size
Status Location
1
First-in-human study
Single ascending dose (SAD) study
- 24 Completed UK
Multiple ascending dose (MAD) study
Safety and Pharmacokinetic (PK) Study
- 16 Completed UK
MAD study
Safety and pharmacokinetic study
- 48 Completed US
Pilot biomarker study NCT00780325 24 Completed US (Univ. of Penn)
Drug-drug interaction (DDI) study NCT01154764 26 Completed Seoul, Korea
Supra-therapeutic MAD study
safety and PK study
NCT01154790 48 Completed Seoul, Korea
2
Placebo controlled proof-of-concept study NCT00530452 248 Completed EU
Celecoxib controlled dose finding study NCT01341405 125 Completed Seoul, Korea
3
Placebo and Celecoxib controlled pivotal
Ph 3 efficacy & safety for approval
and extended safety study
NCT01765296 362 Completed Seoul, Korea

15. 1
Compiled Summary of Completed Studies
Clinical Studies Summary
Phase 1 studies
• Dose dependent exposure observed.
• No significant PK differences among different ethnic and gender groups.
• Clearly differentiated whole blood vs. plasma distribution of polmacoxib – Proof of
polmacoxib-CA binding (75 80x higher conc. in whole blood vs. plasma).∼
• No drug-drug interaction observed.
• Stable blood pressure maintained throughout entire duration of clinical studies
• Absence of significant side effects even in the supra-therapeutic MAD Study
• Cardiovascular safety – Various measurements including ECG, Holter monitoring, vital
signs, and blood chemistry lab tests did not indicate signs of CV adverse events.
• Gastrointestinal safety – Absence of significant GI adverse events
Phase 2a study
• Clinically significant efficacious dose = 1.2 mg per day
• No drop outs due to lack of efficacy
• Maintenance of stable blood pressure throughout entire study

16. 1
Compiled Summary of Completed Studies
Clinical Studies Summary
Phase 2b study
• Non-inferiority tests: polmacoxib 2 mg/day and 4 mg/day vs. celecoxib 200 mg/day
• Uniform dosing on Days 1-28 (no loading dose)
• Very high study drug compliance rates (81-85% in all groups)
• Few dropouts (93-95% completion rate among all 3 treatment arms)
• Polmacoxib 2 mg and 4 mg were non-inferior to celecoxib 200 mg for all efficacy
measures
• Polmacoxib 2 mg dose produced higher efficacy than celecoxib 200 mg, though not
statistically significant (study was not powered for superiority)
• No drop outs due to lack of efficacy
• Polmacoxib 2 mg has a favorable adverse effect profile (comparable to celecoxib 200 mg)
• Polmacoxib 2 mg dose selected for Phase 3 clinical studies
Phase 3 study
• Effficacy (6 week study)
Superiority of polmacoxib 2 mg once-daily vs. placebo
Non-inferiority of polmacoxib 2 mg once-daily vs. celecoxib 200 mg once-daily
• Long Term Safety (6 month study)
No drug-related serious adverse events in either of the polmacoxib or celecoxib groups.
Most of the adverse events were mild to moderate and were expected to happen in this
type of trial.

17. 1
Phase III Clinical Study
Summary

18. 1
Phase III Study: Study Title & The Objectives
Study Title:
A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III
Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients
Objectives:
The objective of the 6-week Efficacy Study was to evaluate the safety and
non-inferiority of the analgesic efficacy of polmacoxib (formerly CG100649) 2 mg
vs. celecoxib 200 mg, and the analgesic superiority of polmacoxib 2 mg vs.
placebo, when administered once daily in subjects with osteoarthritis of
the hip or knee over the 6 week treatment period.
The objective of the Extension Study was to collect a total of 24 weeks of
safety data for those subjects who agreed to continue into the extension.
Study Title and the Objectives of the Study

19. 1
Acelex®
, Phase III Study Results
71.9% of subjects taking Acelex experienced improvement in
signs and symptoms of osteoarthritis
*PGA (Physician’s Global Assessment ): Evaluation of the test subjects by the investigators (physicians)
Acelex showed SUPERIOR EFFICACY over celecoxib with statistical significance (p = 0.005)
Overall improvement of signs and symptoms of osteoarthritis in terms of PGA* scores at week 3

20. 2
Acelex®
, Phase III Study Results
Acelex showed QUICKER ONSET OF RELIEF from osteoarthritis symptoms over celecoxib
Acelex showed statistically significant superiority over placebo at
Week 3 (p=0.003), but celecoxib did NOT show statistically
significant differentiation from placebo at Week 3 (p=0.069)
WOMAC Physical Function scores at Week 3
Acelex demonstrated non-inferior or better efficacy against celecoxib in all other efficacy endpoints
including WOMAC-pain and –stiffness subscales at week-3 and week-6

21. 2
Safety Results from the 6-week Efficacy Study
 There were no drug-related serious adverse events in either of the polmacoxib or
celecoxib treatment groups.
 Most of the adverse events were mild to moderate and were expected to happen
in this type of trial.
 There were no statistically significant differences in all three groups.
Phase III Study: Safety (6-week Treatment Period)

22. 2
Polmacoxib has successfully met the clinical study endpoints as the 2 mg dose of
polmacoxib was tolerated well and based on the results of the 6 week treatment period,‑
polmacoxib 2 mg demonstrated analgesic efficacy and safety similar to that of celecoxib
200 mg, and analgesic superiority over that of placebo.
However, based on the secondary endpoints of WOMAC-Physical function at Week 3 and
PGA at Week 3, the efficacy profile of polmacoxib was superior in comparison with
celecoxib. This suggests that polmacoxib 2 mg achieves a quicker onset of relief from the
signs and symptoms of osteoarthritis compared to celecoxib 200 mg.
The Treatment Emergent Adverse Events (TEAEs) were reported in this study were
generally mild and of the type expected for COX-2 inhibitor drugs.
There were no clinically meaningful or statistically significant differences in the number of
TEAEs among the groups treated with polmacoxib 2 mg, celecoxib 200 mg or placebo.
Phase III Study: Conclusions (6-week Treatment Period)
Conclusions

23. 2
Phase III Study: Extended Safety Study
Safety Conclusions from Safety Extension Study (24 weeks)
• Only polmacoxib 2mg administered (open-label, single arm)
 There were no drug-related serious adverse events.
 During the safety extension study, the 2mg dose of polmacoxib was tolerated well
and TEAEs were generally mild.
 There were no notable increases in the incidence of any TEAEs during the 18-week
safety extension period, or the combined 24-week extended safety period.
 There were no clinically relevant findings in the analysis of clinical laboratory tests,
vital signs, ECGs, or physical examination results.

24. 2
Category Projected Advantages of Acelex
Efficacy
• ​Demonstrated quicker onset of relief from the signs and symptoms of OA over Celebrex.
• Achieved superior PGA (Physicians Global Assessment) scores, than Celebrex with
statistically significance, an efficacy endpoint for measuring the physicians’ perception of
patient improvement in terms of the OA signs and symptoms.
Dose
• Able to achieve therapeutic efficacy (OA) with only 2 mg/day dose, the lowest dose
among all known NSAIDs (both non-selective and selective COX-2 inhibitors).
Administration
Frequency
• Convenient once-a-day dosing regimen
→ The administration frequencies of most commercially available traditional NSAIDs and
incrementally modified NSAID containing products for OA range between b.i.d (twice
daily) through t.i.d (three times daily).
Gastrointestinal
Side Effects
• Acelex has significantly improved GI safety profile in comparison with other commercially
available NSAIDs.
• The GI safety profile of Acelex eliminates the need for concomitant administration of GI
protectant agents.
Cardiovascular
Side Effects
• Acelex’s unique mode of action is projected to provide a meaningful enhancement of
cardiovascular safety from currently available NSAID products.
Product Profile of Acelex

25. 2
Launch of 2 mg
Capsule 2015
Generic Entry Block
2026~2034
• Launch in Korea
• Export or Out-Licensing
• Expansion of Acelex portfolio through development of combination products,
incrementally modified products, new dosage forms, and additional indications.
• Goal is to maintain exclusive position up to 2026~2034 and maximize revenues.
Acelex®
, Lifecycle Management Strategy
Strengthening of the Acelex brand name through launch of multiple products

26. 2
CrystalGenomics, Inc.
5th
F. Bldg.A, Korea Bio Park
700 Daewangpangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do 463-400
Korea
CG Pharmaceuticals, Inc.
5980 Horton Street, Suite 610
Emeryville, CA 94608
U.S.A.